pharma · Retinitis Pigmentosa
GenSight Biologics
GenSight Biologics S.A.
GenSight Biologics is a pharma organization headquartered in EU. Primary therapeutic focus areas include Retinitis Pigmentosa. NovaPharmaNews links 2 clinical program(s), 0 drug profile(s), and 0 patent record(s) to this
paris, FR HQ
2013 Founded
34 Employees
EMA registrant Type
Company details
- Status
- Public
- HQ
- paris, FR
- Founded
- 2013
- Employees
- 34
- Programs
- 2
- Drugs
- 2
- Patents
- 0
Lumevoq
Phase 2 · small molecule · Leber Hereditary Optic Neuropathy due to mutations in the mitochondrial NADH Dehydrogenase 4 gene
Lumevoq for Leber Hereditary Optic Neuropathy due to mutations in the mitochondrial NADH Dehydrogenase 4 gene is a Phase 2 program (small_molecule) at GenSight Biologics S.A. with 1 ClinicalTrials.gov record(s).
Internal code GS-LHON-CLIN-08
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- GenSight Biologics S.A.
- Phase
- Phase 2
- Modality
- small_molecule
- Indication
- Leber Hereditary Optic Neuropathy due to mutations in the mitochondrial NADH Dehydrogenase 4 gene
- Status
- active
- Trials
- 1